Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 Vaccine in a Patient With Clinically Confirmed PEG Allergy

Bibliographic Details
Title: Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 Vaccine in a Patient With Clinically Confirmed PEG Allergy
Authors: Morgan D. McSweeney, Manoj Mohan, Scott P. Commins, Samuel K. Lai
Source: Frontiers in Allergy, Vol 2 (2021)
Publisher Information: Frontiers Media S.A., 2021.
Publication Year: 2021
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: vaccine allergy, vaccine adverse event, anaphylaxis, polyethylene glycol, anti-PEG antibodies, liposome, Immunologic diseases. Allergy, RC581-607
More Details: Although allergic responses to the mRNA COVID-19 vaccines are rare, recent reports have suggested that a small number of individuals with allergy to polyethylene glycol (PEG), a component of the mRNA lipid nanoshell, may be at increased risk of anaphylaxis following vaccination. In this report, we describe a case of a patient who received an mRNA COVID-19 vaccine, experienced anaphylaxis, and was subsequently confirmed to have anti-PEG allergy by skin prick testing. The patient had previously noticed urticaria after handling PEG powder for their occupation and had a history of severe allergic response to multiple other allergens. Importantly, as many as 70% of people possess detectable levels of anti-PEG antibodies, indicating that the detection of such antibodies does not imply high risk for an anaphylactic response to vaccination. However, in people with pre-existing anti-PEG antibodies, the administration of PEGylated liposomes may induce higher levels of antibodies, which may cause accelerated clearance of other PEGylated therapeutics a patient may be receiving. It is important to improve awareness of PEG allergy among patients and clinicians.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2673-6101
Relation: https://www.frontiersin.org/articles/10.3389/falgy.2021.715844/full; https://doaj.org/toc/2673-6101
DOI: 10.3389/falgy.2021.715844
Access URL: https://doaj.org/article/7bcc3d3447d44db7b6e94384610c9ab5
Accession Number: edsdoj.7bcc3d3447d44db7b6e94384610c9ab5
Database: Directory of Open Access Journals
More Details
ISSN:26736101
DOI:10.3389/falgy.2021.715844
Published in:Frontiers in Allergy
Language:English